Stifel Nicolaus raised their target price on Insmed from $121.00 to $145.00 and gave the stock a “buy” rating in a research note on Thursday, August 14th. Nineteen equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. In the last three months, insiders sold 277,332 shares of company stock valued at $33,842,327. FNY Investment Advisers LLC purchased a new position in shares of Insmed in the 2nd quarter valued at about $33,000. Insmed Price PerformanceThe stock’s 50 day moving average is $131.39 and its two-hundred day moving average is $98.41.